Anacor Conference Posters

Date

Conference

May 14-18, 2008
Kyoto, Japan

International Investigative Dermatology Conference

P84	Preclinical toxicology of AN2728, a novel oxaborole in development for the topical treatment of psoriasis
P86	AN2898, a novel oxaborole compound with anti-inflammatory activity: mechanism of action and in vitro cytokine inhibition
P88	Structure-activity studies of AN2728 and AN2898, novel oxaborole compounds with anti-inflammatory activity
P89	In vitro activity and mechanism of action of AN2728, a novel oxaborole in development for treatment of psoriasis.
P90	AN2898, a novel oxaborole compound with anti-inflammatory activity: results of in vivo efficacy and preclinical safety studies
P367	AN2728, a novel oxaborole in development for treatment of psoriasis, demonstrates significant activity in a micro plaque study

Feb. 2 - 6, 2007 Washington, DC

American Academy of Dermatology, 65th Annual Meeting

P406	AN0128 inhibits pro-inflammatory cytokine production in a macrophage cell line by inhibiting the p38 MAP kinase signal transduction pathway
P421	AN2728, A novel Oxaborole with broad-spectrum in-vitro anti-inflammatory activity
P717	A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN0128 1% Cream for the Treatment of Mild to Moderate Atopic Dermatitis
P1800	In vitro Nail Penetration Of AN2690, Effect Of Vehicle And Coefficient Of Efficacy
P1802	Interim Results of a Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solutions for the Treatment of Onychomycosis of the Great Toenail
P1816	In vivo nail residence time of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis
P1823	An Open-Label, Multiple-Dose Study of the Absorption and Systemic Pharmacokinetics of AN2690 Applied as a 7.5% Solution to All Toenails of Adult Patients with Moderate to Severe Onychomycosis
P2703	Medicinal Chemistry Development Of AN2728, A Novel Oxaborole In Development For The Topical Treatment Of Psoriasis
P2712	Skin Penetration And Anti-Inflammatory Activity of AN2728, A Novel Oxaborole

Oct. 29 - Nov. 2, 2006
San Antonio, TX

American Association of Pharmaceutical Scientists, Annual Meeting

Oct. 1 - 6, 2006
San Diego, CA

2006 International Conference on Aminoacyl-tRNA synthetases: From the Genetic Code to Human Diseases & Medicine

Sept. 10 - 14, 2006
San Francisco, CA

232nd ACS National Meeting

Medi332

Sept. 7 - 9,2006
Paris, France

European Society For Dermatological Research, 36th Annual Meeting

P91	Nail Penetration Of AN2690: Efficacy Coefficient And Effect of Formulation
P94	New AN0128 Formulations Improve In Vitro Skin Penetration and In Vivo Efficacy
P346	AN0128 Inhibits Pro-inflammatory Cytokine Production in a Macrophage Cell Line by Inhibiting the p38 MAP Kinase Signal Transduction Pathway
P565	Interim Results of a Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solutions for the Treatment of Onychomycosis of the Great Toenail
P566	An Open-Label, Multiple-Dose Study of the Absorption and Systemic Pharmacokinetics of AN2690 Applied as a 7.5% Solution to All Toenails of Adult Patients with Moderate to Severe Onychomycosis
P567	A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Topically Applied AN0128 1% Cream for the Treatment of Mild to Moderate Atopic Dermatitis

May 3-6, 2006
Philadelphia, PA

Society for Investigative Dermatology, 67th Annual Meeting

P750	In vitro Nail Penetration Profile Of AN2690, A Novel Broad-Spectrum Antifungal Agent In Development For The Topical Treatment Of Onychomycosis
P769	AN2690, a topical antifungal agent in development for the treatment of onychomycosis represents a new class and has a novel mechanism of action
P775	Medicinal Chemistry Of AN2690, A Novel Broad-Spectrum Antifungal Agent In Development For The Topical Treatment Of Onychomycosis

April 19, 2006
La Grande Motte, France

Perspectives in Percutaneous Penetration (PPP), 10th International Conference

March 3 - 7, 2006
San Francisco, CA

American Academy of Dermatology, 64th Annual Meeting

P103	A Novel Borinic Acid Ester With Antibacterial Activity Against Propionibacterium acnes
P104	A Novel Synthetic Borinic Acid Ester with a Broad Spectrum of Antibacterial Activity
P108	AN0128, A Novel Borinic Acid Ester with In Vitro and In Vivo Anti-Inflammatory Activity
P122	Preclinical Toxicology of AN0128, A Novel Borinic Acid Ester with Combined Antimicrobial and Anti-Inflammatory Activity
P145	Clinical Safety of AN0128, a Novel Borinic Acid Ester
P800	A Novel Borinic Acid Ester with Antibacterial Activity Against Staphylococcus aureus
P1607	Initial Characterization of Resistant Mutants to AN2690, A New Antifungal Agent in Development for the Topical Treatment of Onychomycosis, Predicts a Novel Mechanism of Action
P1608	Microbiological Activity of AN2690, a New Antifungal Agent in Development for the Topical Treatment of Onychomycosis
P1611	Preclinical Toxicology of AN2690, A New Antifungal Agent in Development for the Topical Treatment of Onychomycosis

For media inquiries please email media@anacor.com.

	SITEMAP \| CONTACT \| PRIVACY POLICY \| TERMS OF USE \| HOME
	© 2008 Anacor Pharmaceuticals, Inc., All Rights Reserved.